Lung Cancer Clinical Trial
IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.
|Start date||June 2010|
|Completion date||August 2012|
Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the
adjuvant Montanide, for treatment of patients with locally advanced or metastatic non
small-cell lung cancer. A first-in-man phase I trial.
Hypothesis: In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.
Background: Non small-cell lung cancer (NSCLC) is a common disease with a poor prognosis
when locally advanced or metastasized, despite advances in surgery, chemo- and radiation
In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.
IDO has recently been recognized as an important factor in immune regulation and development of immune tolerance in the microenvironment of cancer cells. Cells that represent IDO at their surface are known to inhibit the immune system. IDO expression is seen both in cancer cells and antigen presenting cells. The vaccination against IDO expressing cells is therefore two-sided. The vaccination therapy is thought to block the development of immune tolerance induced by IDO expressing cells. At the same time the investigators aim to stimulate the production of IDO specific T-cells, hence facilitating the elimination of IDO positive tumour cells. The primary end points are safety and toxicity evaluation. Secondary end points are immunological and clinical response.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|Recruiting||NCT02513563 - AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer||Phase 2|
|Completed||NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data||N/A|
|Not yet recruiting||NCT03195491 - A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia||Phase 3|
|Recruiting||NCT02538666 - An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy||Phase 3|
|Not yet recruiting||NCT02676050 - Visualising c-MET and Activated Neutrophils in Lung Cancer||Phase 1|
|Recruiting||NCT02939729 - Physiotherapy Prehabilitation in Patients Undergoing Cardiac or Thoracic Surgery||N/A|
|Recruiting||NCT03050047 - A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors||Phase 1|
|Recruiting||NCT03009630 - ENB Guided RFA for Early-stage Peripheral Lung Cancer||N/A|
|Recruiting||NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors||Phase 1|
|Recruiting||NCT02869789 - An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers||Phase 3|
|Not yet recruiting||NCT02795923 - Nivolumab Alone or in Combination With Decitabine/Tetrahydrouridine in Non-small Cell Lung Cancer||Phase 2|
|Recruiting||NCT02444741 - MK-3475 and Stereotactic Body Radiation Therapy (SBRT) in Patients With Non-Small Cell Lung Cancer (NSCLC)||Phase 1/Phase 2|
|Recruiting||NCT02558101 - Lung Screen Uptake Trial||N/A|
|Recruiting||NCT02507778 - Circulating Tumor Cells Spillage After Pulmonary Biopsy||N/A|
|Recruiting||NCT02196844 - Yoga Program for Lung Cancer Patients and Caregivers||N/A|
|Recruiting||NCT02115464 - Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy||Phase 2|
|Recruiting||NCT02308709 - Novel Lung Functional Imaging for Personalized Radiotherapy||N/A|
|Completed||NCT02106143 - RejuvenAir™ System Lobectomy Safety and Histology Study||N/A|
|Completed||NCT02771470 - Intestinal Microflora in Lung Cancer After Chemotherapy||Phase 1|
|Completed||NCT02233842 - Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors||N/A|